St. Dominic Hospital recently acquired the DigniCap Scalp Cooling System to minimize hair loss from chemotherapy.
Positive results from the multi-center FDA clinical trial, published in February 2017 by “The Journal of the American Medical Association” (JAMA), indicate that seven out of 10 patients using the DigniCap® system kept at least 50 percent of their hair.
“For many patients hair loss is a very troublesome side effect of chemotherapy,” said Christy Haygood, MD, gynecologic oncologist. “DigniCap provides patients with a means to reduce hair loss while maintaining their privacy and self-esteem. We believe this is a significant advantage in caring for the whole patient and are proud to make this technology available to patients at St. Dominic’s.”
FDA-cleared since 2015, the DigniCap® Scalp Cooling System minimizes hair loss from certain chemotherapy treatments for women and men with solid tumor cancers such as those associated with breast, ovarian, uterine, prostate and other tissues.
The DigniCap Scalp Cooling System features a patented tight-fitting silicone cooling cap that is placed directly on the head and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit with touch screen prompts.
A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp.
The cap is fitted to the head, and the temperature of the scalp is lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to decreased intra follicular metabolic rate.
These factors together reduce the risk of chemotherapy-induced hair loss.